ReviewNature reviews. Drug discovery2022
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
Review in Nature reviews. Drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 287 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
287 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Outcomes and Predictors of Sustained Response After Dose Tapering of Targeted Therapies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review.American journal of clinical dermatology · 2026Pooled it
- Effectiveness of Systemic Treatments for Atopic Dermatitis in the Head-and-Neck-Area: A Systematic Review and Meta-analysis.American journal of clinical dermatology · 2026Pooled it
- Pooled it
- A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.CPT: pharmacometrics & systems pharmacology · 2026Pooled it
- Effects of dupilumab on quality of life in patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review.PloS one · 2024Pooled it
- Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial.Chinese medical journal · 2026Trial
- S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double-blind randomized clinical trial in patients with mild to moderate atopic dermatitis.British journal of clinical pharmacology · 2026Trial
- Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.American journal of clinical dermatology · 2025Trial
- The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.Nature communications · 2024Trial
- Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Trial
- Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies.Archives of dermatological research · 2024Trial
- Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.The British journal of dermatology · 2024Trial
- The enteric DNA virome differs in infants at risk for atopic disease.Gut microbes · 2026Article
- Single-cell transcriptome revealed the aberrant keratinocytes activation in antigen presentation in atopic dermatitis.Annals of medicine · 2026Article
- Aqueous extract ofPharmaceutical biology · 2026Article
- High-salt microenvironment worsens the progression of atopic dermatitis via activating the SGK-1-mTOR pathway in keratinocytes.Genes & diseases · 2026Article
- Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.Dermatology and therapy · 2026Article
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.Dermatology and therapy · 2026Article
227 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti-IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.